Evaluation of Neuromuscular Blockade Responses in Statin-Using and Non-Using Patients

Evaluation of Neuromuscular Blockade Responses in Statin-Using and Non-Using Patients Undergoing Elective Surgery Under General Anesthesia, Monitored by Train-of-Four (TOF)

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06834776

Enrollment

104

Registered

2025-02-19

Start date

2025-02-15

Completion date

2025-12-15

Last updated

2025-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromuscular Blockade, Neuromuscular Monitoring, Statin-Associated Myopathy

Brief summary

This study aims to compare the neuromuscular blockade responses in patients undergoing elective surgery under general anesthesia, with a focus on the use of statins. The study will assess the depth of neuromuscular blockade, recovery time, and postoperative residual curarization using Train-of-Four (TOF) monitoring, with the primary goal of determining whether statin use alters the neuromuscular blockade management.

Interventions

DIAGNOSTIC_TESTTOF (Train-of-Four) monitoring for depth of neuromuscular blockade.

General anesthesia with propofol and fentanyl induction followed by rocuronium for neuromuscular blockade; maintenance with desflurane and remifentanil.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Age 18-75 years * ASA classification I, II, III * BMI 18-30 * Statin use for at least 3 months or no prior statin use * Elective surgery requiring general anesthesia with endotracheal intubation * Signed informed consent for participation in the study

Exclusion criteria

* ASA classification IV or higher * BMI \<18 or \>30 * History of liver or renal insufficiency (creatinine \>1.6, liver function tests \>2x normal) * Neuromuscular, psychiatric, or neurological disorders * Pregnancy * Use of drugs affecting neuromuscular function (e.g., anticonvulsants, aminoglycosides) * History of malignant hyperthermia * Respiratory disorders, including sleep apnea * Allergy to anesthetic drugs used in the study

Design outcomes

Primary

Measure	Time frame	Description
Time to reach TOF count 0	0th minute	time from administration of rocuronium to reach TOF count 0
Time to reach TOF 40	about 40th minute	time to intraoperatively TOF reached 40
Time to reach TOF 90 (reversal of neuromuscular blockade)	about 60th minute	Measured postoperatively after sugammadex administration and additional doses if required.

Contacts

Primary Contactismail aytaç, assoc. Prof. Dr

aytacismail1972@gmail.com+905056340369

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026